Bleeding disorder of unknown cause: an illustrated review on current practice, knowledge gaps, and future perspectives

In more than half of the individuals with a clinically relevant bleeding tendency who are referred to hemostasis experts, no biological etiology can be found after extensive laboratory testing. These persons are diagnosed with an unexplained bleeding tendency or "bleeding disorder of unknown cause" (BDUC). The mucocutaneous bleeding phenotype of individuals with BDUC is generally comparable to that of individuals with inherited bleeding disorders such as von Willebrand disease or platelet function disorders. BDUC definitions applied in literature are heterogeneous, but all comprise 2 main criteria: (1) there is an increased bleeding tendency based on the clinical view of the physician and/or an increased bleeding score; (2) no abnormalities are found with available hemostasis laboratory tests. This is reflected in the recent published BDUC definition by the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, stating that BDUC is a diagnosis of exclusion, characterized by normal hemostatic investigations despite a clinically significant bleeding tendency. Importantly, other nonhemostatic and acquired causes of bleeding should be excluded, but details on exclusion criteria and associated diagnostic testing remain undefined. Patients and health care providers are challenged by the uncertainty and lack of formal diagnosis particularly as there is no clear consensus regarding treatment. Research on the diagnostic value of new laboratory tests in individuals with BDUC has not yet been productive. In this illustrative review, the current practice and knowledge gaps in BDUC are addressed, previous research on BDUC is outlined and future directions with outstanding questions for future research in BDUC are highlighted.

Authors

Institutions

Publication Details

Journal
Research and Practice in Thrombosis and Haemostasis
Published
2024-11-01
DOI
https://doi.org/10.1016/j.rpth.2024.102625
Citations
6
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
2.41
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bleeding disorder of unknown cause: an illustrated review on current practice, knowledge gaps, and future perspectives

James S. O’Donnell, Paul L. den Exter, Iris van Moort, Ross Baker et al.
6 citations
Research and Practice in Thrombosis and Haemostasis
Atrial Fibrillation Management and Outcomes
2.41
article

Bleeding disorder of unknown cause: an illustrated review on current practice, knowledge gaps, and future perspectives

James S. O’Donnell, Paul L. den Exter, Iris van Moort, Ross Baker, Tirsa T van Duijl, Marjon H. Cnossen, Saskia E.M. Schols, Maartje van den Biggelaar, Laurens Nieuwenhuizen, Roger E. G. Schutgens, Karina Meijer, Floor Heubel-Moenen, Yvonne Henskens, Marieke J.H.A. Kruip, Amaury Monard, Caroline Mussert, Karin J. Fijnvandraat
article en
6 citations

Abstract

In more than half of the individuals with a clinically relevant bleeding tendency who are referred to hemostasis experts, no biological etiology can be found after extensive laboratory testing. These persons are diagnosed with an unexplained bleeding tendency or "bleeding disorder of unknown cause" (BDUC). The mucocutaneous bleeding phenotype of individuals with BDUC is generally comparable to that of individuals with inherited bleeding disorders such as von Willebrand disease or platelet function disorders. BDUC definitions applied in literature are heterogeneous, but all comprise 2 main criteria: (1) there is an increased bleeding tendency based on the clinical view of the physician and/or an increased bleeding score; (2) no abnormalities are found with available hemostasis laboratory tests. This is reflected in the recent published BDUC definition by the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, stating that BDUC is a diagnosis of exclusion, characterized by normal hemostatic investigations despite a clinically significant bleeding tendency. Importantly, other nonhemostatic and acquired causes of bleeding should be excluded, but details on exclusion criteria and associated diagnostic testing remain undefined. Patients and health care providers are challenged by the uncertainty and lack of formal diagnosis particularly as there is no clear consensus regarding treatment. Research on the diagnostic value of new laboratory tests in individuals with BDUC has not yet been productive. In this illustrative review, the current practice and knowledge gaps in BDUC are addressed, previous research on BDUC is outlined and future directions with outstanding questions for future research in BDUC are highlighted.

Research and Practice in Thrombosis and HaemostasisVol. 8(8)
University Medical Center Groningen (NL), Royal College of Surgeons in Ireland (IE), Radboud University Nijmegen (NL), Murdoch University (AU), Utrecht University (NL), Leiden University Medical Center (NL), Erasmus MC (NL), Radboud University Medical Center (NL), Sanquin (NL), Maastricht University (NL), Emma Kinderziekenhuis (NL), Máxima Medisch Centrum (NL), Erasmus MC - Sophia Children’s Hospital (NL), Amsterdam University Medical Centers (NL)
Gender equality
Openalex Percentile: Top 9%
Atrial Fibrillation Management and Outcomes
2.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.